The goal of this collaboration is to improve the selective targeting of lentiviral vectors in vivo to tumor cells after intratumoral injection of vectors carrying shRNAs. The project focuses on the use of camlid natural single chain immunoglobulin to CEA, a tumor marker expressed on nearly all human adenocarcinomas. This may be an extremely important step in adapting RNAi to clinical use.